Biomerica vs Insight Molecular Diagnostics
BMRA and IMDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRA and IMDX compare
Insight Molecular Diagnostics is the larger company, worth 10 times as much as Biomerica ($58.2M against $5.7M).
Biomerica grew revenue faster over the last twelve months (−11.2% versus −60.8% for Insight Molecular Diagnostics).
Biomerica keeps more of each dollar of sales as profit, with a net margin of −115% compared with −2956% at Insight Molecular Diagnostics.
Biomerica scores higher on the StockData Score (8 against 7 for Insight Molecular Diagnostics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRA | IMDX |
|---|---|---|
| Size and price | ||
| Market cap | $5.7M | $58.2M |
| Share price | $1.24 | $1.78 |
| Change, 1 year | −48.8% | −75.9% |
| Change, 5 years | −96.9% | −96.3% |
| Beta (5Y) | 0.93 | 2.66 |
| Employees | 17 | 58 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.3× (better) | 34.9× |
| P/B | 1.6× | – |
| FCF yield | – | −53.2% |
| Fair value | $2.44 | – |
| Margin of safety | 49.4% | – |
| Growth | ||
| Revenue growth (TTM) | −11.2% (better) | −60.8% |
| Revenue growth, 5Y average | −9.2% | 27.2% (better) |
| Profitability | ||
| Gross margin | 0.90% | 48.3% (better) |
| Operating margin | −125% (better) | −3012% |
| Net margin | −115% (better) | −2956% |
| FCF margin | – | −1856% |
| Return on equity | −114% | – |
| Return on invested capital | −284% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Current ratio | 1.91 | 2.00 (better) |
| Altman Z-score | −10.62 (better) | −24.27 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Buyback yield | −55.7% | −44.7% (better) |
| Shareholder yield | −55.7% | −44.7% (better) |
| Ownership | ||
| Held by institutions | 2.7% | 56.4% |
| Held by insiders | 27.4% | 81.6% |
| Insider net buying, 12 months | $158K | $5.7M (better) |
| Short interest, % of float | 0.37% | 17.0% |
Go deeper
- BMRA stock overview
- BMRA income statement
- BMRA valuation and score
- IMDX stock overview
- IMDX income statement
- IMDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.